CR20250551A - Bloqueadores de canales de sodio - Google Patents

Bloqueadores de canales de sodio

Info

Publication number
CR20250551A
CR20250551A CR20250551A CR20250551A CR20250551A CR 20250551 A CR20250551 A CR 20250551A CR 20250551 A CR20250551 A CR 20250551A CR 20250551 A CR20250551 A CR 20250551A CR 20250551 A CR20250551 A CR 20250551A
Authority
CR
Costa Rica
Prior art keywords
sodium channel
channel blockers
modulate
disorders
treating
Prior art date
Application number
CR20250551A
Other languages
English (en)
Inventor
Tyler Harrison
Michael Doré
Robert Francis Day
Efthymiou Hatice Belgin Gulgeze
Tajesh Patel
Sii Hong Lau
Jay Francis Larrow
Haihao Tang
Xiang Gao
Adam Friedman
Sandra Marie King
Yunshan Peng
Nichola Smith
Yanxiang Wu
Christian Michael Gampe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20250551A publication Critical patent/CR20250551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La presente divulgación se refiere a compuestos de sulfonamida, a su uso para modular el canal de sodio Nav1.5, y a métodos para tratar o prevenir enfermedades, trastornos o afecciones usando los mismos.
CR20250551A 2023-07-07 2024-07-05 Bloqueadores de canales de sodio CR20250551A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023106400 2023-07-07
PCT/CN2024/103810 WO2025011450A1 (en) 2023-07-07 2024-07-05 Sodium channel blockers

Publications (1)

Publication Number Publication Date
CR20250551A true CR20250551A (es) 2026-01-19

Family

ID=94214640

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20250551A CR20250551A (es) 2023-07-07 2024-07-05 Bloqueadores de canales de sodio

Country Status (12)

Country Link
US (1) US20250034108A1 (es)
KR (1) KR20260035224A (es)
CN (1) CN121548572A (es)
AR (1) AR133184A1 (es)
AU (1) AU2024296422A1 (es)
CO (1) CO2025019045A2 (es)
CR (1) CR20250551A (es)
DO (1) DOP2025000336A (es)
IL (1) IL325153A (es)
MX (1) MX2026000100A (es)
TW (1) TW202502310A (es)
WO (1) WO2025011450A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2620179C (en) * 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
US9630929B2 (en) * 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
HRP20250505T1 (hr) * 2016-05-20 2025-06-20 Xenon Pharmaceuticals Inc. Spojevi benzensulfonamida i njihova uporaba za terapijska sredstva
ES2967410T3 (es) * 2016-12-09 2024-04-30 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos en forma de agentes terapéuticos
TW202003490A (zh) * 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
MA53488A (fr) * 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MX2021001380A (es) * 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
WO2020052509A1 (zh) * 2018-09-10 2020-03-19 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Also Published As

Publication number Publication date
MX2026000100A (es) 2026-03-02
AU2024296422A1 (en) 2025-12-18
WO2025011450A9 (en) 2026-01-15
CN121548572A (zh) 2026-02-17
DOP2025000336A (es) 2026-03-15
US20250034108A1 (en) 2025-01-30
KR20260035224A (ko) 2026-03-12
WO2025011450A1 (en) 2025-01-16
CO2025019045A2 (es) 2026-01-23
IL325153A (en) 2026-02-01
AR133184A1 (es) 2025-09-03
TW202502310A (zh) 2025-01-16

Similar Documents

Publication Publication Date Title
CO2021006098A2 (es) Moduladores de profármacos de la vía de estrés integrada
CL2022003434A1 (es) Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378)
CL2022001083A1 (es) El uso de un modulador de empalme para un tratamiento que retrasa la progresión de la enfermedad de huntington
UY38685A (es) Moduladores de la vía de tensión integrada
CO2022008969A2 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2021015668A2 (es) Moduladores de la vía integrada del estrés
CO2024010861A2 (es) Moduladores stat y usos de los mismos
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
CR20220059A (es) Mezclas que comprenden plaguicidas de indazol
PA8577001A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
BRPI0408026A (pt) Quinazolinas úteis como moduladores de canais de ìon
MX2020004538A (es) Moduladores de la vía de estrés integrada.
GT200300054A (es) Compuestos que modulan la actividad de ppar
ECSP21013035A (es) Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapéuticos
CO2019005552A2 (es) Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CR8926A (es) Acidos de tiazolo-naftilo
GEAP202516611A (en) Nlrp3 modulators
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2022011333A (es) Compuestos moduladores de gpr52.
ECSP23040124A (es) Moduladores de la vía integrada del estrés
AR134204A1 (es) Nuevos compuestos como moduladores de los canales de sodio y usos de los mismos
CO2025019045A2 (es) Bloqueadores de canales de sodio
MX2023002389A (es) Compuestos moduladores de gpr52.
MX2021004647A (es) Formas cristalinas de moduladores de los canales de potasio.
MX2019008078A (es) Moduladores de receptores neuropeptido basados en prolina.